The clinical utility of tumor markers

Laboratory Medicine

Volumn 40, Issue 2, 2009, Pages 99-103

  Handy, Beverly ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LACTATE DEHYDROGENASE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BRAIN METASTASIS; BREAST CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; OVARY CARCINOMA; PATIENT MONITORING; REVIEW; TREATMENT PLANNING;

EID: 77956954954     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMTRKSKYW4GI6SBJ     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Lipscomb J. Estimating the cost of cancer care in the United States: A work very much in progress. J Natl Cancer Inst. 2008;100:607-610.
3. National Cancer Institute. Cancer trends progress report - 2007 update. Available at: http://progressreport.cancer.gov. Accessed on: August 9, 2008.
4. Genetics Home Reference. Unified medical language system (NCI Thesaurus) - National Library of Medicine. Available at: http://ghr.nlm.nih.gov/glossary. Accessed on: August 5, 2008.
5. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med. 1991;115:623-638.
6. Wu JT. Diagnosis and management of cancer using serologic tumor markers. In Henry JB, ed. Clinical Diagnosis and Management by Laboratory Methods. 20th ed. Philadelphia, PA: WB Saunders; 2001: 1028-1042.
7. Tetrault, GA. Laboratory statistics. In Henry JB, ed. Clinical Diagnosis and Management by Laboratory Methods. 20th ed. Philadelphia, PA: WB Saunders; 2001: 138-147
8. Trigo JM, Tabernero JM, Paz-Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88:162-168. (Pubitemid 30027692)
9. Gion M, Mione R, Leon AE, et al. Comparison of the diagnostic accuracy of CA 27.29 and CA 15.3 in primary breast cancer. Clin Chem. 1999;45:630-637.
10. Gum JR. Mucin genes and the proteins they encode: Structure, diversity and regulation. Am J Respir Cell Mol Biol. 1992;7:557-564.
11. Klee GG, Schreiber WE. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR) - Are they measuring the same antigen? Arch Pathol Lab Med. 2004;128:1131-1135.
12. Bon GG, von Mensdorff-Pouilly S, Kenemans P, et al. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15.3 assays. Clin Chem. 1997;43:585-593.
13. Lumachi F, Basso SMM. Serum tumor markers in patients with breast cancer. Expert Rev Anticancer Ther. 2004;4:921-931. (Pubitemid 39359875)
14. Beveridge RA. Review of clinical studies of CA27.29 in breast cancer management. Int J Biol Markers. 1999;14:36-39.
15. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplication of the HER-2/neu ongogene. Science. 1987;235:177-183.
16. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
17. Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer. The importance of accurate epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008;132:1008-1015.
18. Cordera F, Jordan VC. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol. 2006;33:631-641. (Pubitemid 44834535)
19. Early Breast Cancer Trialists' Collaborative Group E: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet. 2005;365:1687-1717.
20. Anderson WF, Chu KC, Chatterjee N, et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results data base. J Clin Oncol. 2001;19:18-27.
21. Lilja H, Oldbring J, Rannevik G, et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80:281-285.
22. Sokoll LJ, Chan DW. Prostate-specific antigen - Its discovery and biochemical characteristics. Urol Clin North Am. 1997;24: 253-259.
23. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - What we have learned and where we are going. J Urol. 1999;162:293-306.
24. Lilja H, Christensson A, Dahlén U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37:1618-1625.
25. Oesterling JE, Chan DW, Epstein JL, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766.
26. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452-1455.
27. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA. 1998;279: 1542-1547.
28. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA. 1993;27:860-864.
29. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815.
30. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseases. JAMA. 1992;26:2215.
31. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urol. 1998;52:372-378.
32. Goslin R, Steele G, Macintyre J, et al. The use of preoperative CEA levels for the stratification of patients after curative resection of colorectal cancers. Ann Surg. 1980;192:747-751. (Pubitemid 11210697)
33. Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncol. 2006;70:255-264.
34. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-5503.
35. Ko AH, Hwang J, Venook AP, et al. Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195-199. (Pubitemid 41133205)
36. Fritsche HA, Bast RC. CA 125 in ovarian cancer: Advances and controversy. Clin Chem. 1998;44:1379-1380.
37. Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-1337.
38. Rubin SC, Hoskins WJ, Hakes TB, et al. Serum CA-125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989;160:667-671. (Pubitemid 19092158)
39. Crawford SM, Peace J. Does nadir CA125 concentration predict a longterm outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005;16:47-50.
40. Jain KK. Cancer biomarkers: Current issues and future directions. Curr Opin Mol Ther. 2007;9:563-571.